Case file · CIK 0001410830
Technology growth manager for semiconductor, platform, and crowding signals.
Q4 2025 · SEC 13F case file
KOL-style case note
Technology growth manager for semiconductor, platform, and crowding signals. This page turns the latest public filing into a shareable research story: what the entity owns, which theme is driving the portfolio, and where to investigate next.
Technology growth manager for semiconductor, platform, and crowding signals. It belongs in a smart-money radar because its public 13F shows quarterly capital direction and theme preference.
The latest filing's largest public position is AURA BIOSCIENCES INC, around 65.5% of the disclosed 13F portfolio. That is the first place to look for the current thesis.
Mixed is the clearest public theme in the portfolio. The important question is whether that theme repeats across the top positions, not just whether one stock worked.
The latest public portfolio is about $57.6M, with 2 lines and roughly 100.0% in the top 10. Higher concentration means a few decisions can explain more of the proxy return.
This is not a live trading signal. It is a quarterly capital map: start with the ranking, inspect the top holdings, then ask whether the manager has a repeatable framework.
13F filings are delayed and incomplete. They do not show shorts, many derivatives, private positions, cash, or current trade timing. Use this page to generate research questions, not to replace diligence.
Smart Money VelocityVelocity score blends 13F value growth, concentration, theme purity, option exposure, and filing history. It is a prioritization score, not a return.
Score blends filing growth, concentration, theme purity, call exposure, and filing history.
13F value
$57.6MQ4 2025, latest public filingGrowth since first filing
0.01x$7.4B → $57.6MReporting lag13F filings arrive after the quarter ends. The page shows a delayed public snapshot, not live positions.
45dQuarter-end snapshot, not live positionsThis is not actual fund performance. Returns and rankings use public disclosures after they become visible, not private NAV or live trading.
Disclosure workflow
Every number is anchored to a public quarterly filing. The report date is the portfolio snapshot; the filing date is when the market could actually see it.
Public holdings
| Holding | Theme | Type | Value | % |
|---|---|---|---|---|
| AURA BIOSCIENCES INC05153U107 · 6,922,870 shares | Other | SH | $37.7M | 65.5% |
| MAZE THERAPEUTICS INC578784100 · 480,000 shares | Other | SH | $19.9M | 34.5% |
Quarter tape
Signal breakdown
13F value is 0.01x the first tracked filing.
Top ten public lines are 100.0% of the latest report.
2 reportable lines in the latest public filing.
12 tracked quarterly 13F reports in the database or seed layer.
Publisher mode
Evidence layer
13F reports disclose long reportable U.S. securities and long put/call options. They do not show cash, private stakes, shorts, written options, or current live holdings.
Theme tags are deterministic product analysis from issuer, CUSIP, option type, and keyword rules. They are not SEC labels.
Vercel Cron calls the EDGAR ingestion endpoint every day and records per-manager ingestion results.
